| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.supriyalifescience.com | |
| Market Cap | 2,870.82 Cr. | |
| Enterprise Value(EV) | 2,664.21 Cr. | 2022-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 18.86 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | 18.91 | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 28.41 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 76.50 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 4.66 | Calculated using Price: 356.70 |
| Dividend Yield | 0.17 | Period Ending 2021-03 |
| No. of Shares Subscribed | 8.05 Cr. | 80,482,800 Shares |
| FaceValue | 2 | |
| Company Profile | ||
|
The company was incorporated as ‘Supriya Lifescience Limited’ pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai (RoC), upon the conversion of ‘M/s Supriya Chemicals’, a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. The company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by RoC. The company is a global leading manufacturer of Active pharmaceutical Ingredients. The company’s pharmaceutical business is organized into domestic and export sales, according to the geographies in which it operates. It has grown its API business in several countries across Europe, Latin America, Asia (excluding India), North America and India. The company’s customers include global pharma companies such as Syntec Do Brasil LTDA, American International Chemical Inc and AT Planejamento E Desenbolvimento De Negocios Ltda, with whom it has business relationship for over nine years, and Suan Farma Inc, Acme Generics LLP, Akum Drugs Ltd and Mankind Pharma Ltd with whom it has business relationship for over four years. Its products are registered with various international regulatory authorities such as USFDA, EDQM, NMPA (previously known as SFDA), KFDA, PMDA, TGA and Taiwan FDA. Business area of the company The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. The company has niche product offerings of various APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic. Awards, accreditations or recognitions
Major events and milestones
|
||
Company Profile
The company was incorporated as ‘Supriya Lifescience Limited’ pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai (RoC), upon the conversion of ‘M/s Supriya Chemicals’, a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. The company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by RoC.
The company is a global leading manufacturer of Active pharmaceutical Ingredients. The company’s pharmaceutical business is organized into domestic and export sales, according to the geographies in which it operates. It has grown its API business in several countries across Europe, Latin America, Asia (excluding India), North America and India. The company’s customers include global pharma companies such as Syntec Do Brasil LTDA, American International Chemical Inc and AT Planejamento E Desenbolvimento De Negocios Ltda, with whom it has business relationship for over nine years, and Suan Farma Inc, Acme Generics LLP, Akum Drugs Ltd and Mankind Pharma Ltd with whom it has business relationship for over four years. Its products are registered with various international regulatory authorities such as USFDA, EDQM, NMPA (previously known as SFDA), KFDA, PMDA, TGA and Taiwan FDA.
Business area of the company
The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. The company has niche product offerings of various APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.
Awards, accreditations or recognitions
Major events and milestones
| 1 Day |
|
-2.33% |
| 1 Week |
|
-7.04% |
| 1 Month |
|
-16.59% |
| 3 Month |
|
-7.59% |
| 6 Month |
|
|
| 1 Year |
|
|
| 2 Year |
|
|
| 5 Year |
|
|
| 10 Year |
|
| 9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 29.89 | 29.57 | 29.61 | 17.20 | 15.05 | 18.38 | 53.11 | 60.42 | 59.23 | |
| Return on Capital Employed (%) | 21.78 | 19.43 | 15.83 | 12.27 | 11.48 | 13.80 | 36.52 | 49.67 | 60.12 | |
| Return on Assets (%) | 5.30 | 5.42 | 5.37 | 2.80 | 2.40 | 3.59 | 15.82 | 24.90 | 31.66 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
| Shh. Funds | 26 | 30 | 37 | 42 | 46 | 55 | 94 | 149 | 269 | 616 | |
| Non Curr. Liab. | 11 | 17 | 23 | 39 | 51 | 45 | 24 | 32 | 31 | 19 | |
| Curr. Liab. | 65 | 83 | 115 | 150 | 144 | 146 | 135 | 155 | 146 | 100 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 101 | 130 | 176 | 231 | 241 | 245 | 253 | 336 | 446 | 735 | |
| Non Curr. Assets | 39 | 52 | 73 | 102 | 126 | 126 | 120 | 138 | 179 | 237 | |
| Curr. Assets | 62 | 78 | 103 | 129 | 115 | 120 | 133 | 198 | 266 | 498 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 101 | 130 | 176 | 231 | 241 | 245 | 253 | 336 | 446 | 735 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Net Sales | 78 | 92 | 113 | 138 | 171 | 184 | 213 | 278 | 312 | 385 | |
| Other Income | 2 | 3 | 2 | 2 | 2 | 7 | 9 | 8 | 11 | 11 | |
| Total Income | 80 | 95 | 115 | 140 | 173 | 191 | 222 | 286 | 323 | 396 | |
| Total Expenditure | -68 | -81 | -98 | -121 | -151 | -166 | -191 | -213 | -213 | -218 | |
| PBIDT | 12 | 14 | 16 | 20 | 22 | 25 | 31 | 73 | 109 | 178 | |
| Interest | -4 | -5 | -6 | -7 | -10 | -12 | -11 | -10 | -7 | -4 | |
| Depreciation | -1 | -2 | -2 | -2 | -4 | -5 | -5 | -5 | -6 | -7 | |
| Taxation | -2 | -3 | -2 | -2 | -2 | -2 | -6 | -18 | -23 | -44 | |
| Exceptional Items | |||||||||||
| PAT | 5 | 5 | 6 | 8 | 6 | 6 | 9 | 39 | 73 | 124 | |
| Adjusted EPS | 14 | 10 | 13 | 17 | 4 | 4 | 6 | 27 | 50 | 17 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | -6 | 14 | 27 | 28 | 49 | 116 | 80 | ||||
| Cash Fr. Inv. | -23 | -33 | -27 | -5 | 5 | -25 | -47 | ||||
| Cash Fr. Finan. | 30 | 21 | -2 | -20 | -50 | -29 | -15 | ||||
| Net Change | 1 | 2 | -2 | 3 | 4 | 62 | 18 | ||||
| Cash & Cash Eqvt | 5 | 7 | 6 | 9 | 12 | 75 | 92 |
|
Mon, 23 May 2022
Statement Of Deviation Or Variation In The Use Of Proceeds Of The Fresh Issue Of The Initial Public Offer Of The Company Pursuant to Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24 2019 please find enclosed herewith statement of deviation(s) or variation(s) in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended March 31 2022 in the prescribed format. Further we hereby confirm that there is no deviation or variation in the utilisation of IPO proceeds from the objects stated in the prospectus dated December 21 2021. Kindly take the same on record and acknowledge the receipt. |
|
Mon, 23 May 2022
Audio Recording Of Earnings Call In accordance with Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the audio recording of the Companys Earnings Call held today (i.e. May 23 2022) regarding discussion on operational and financial performance for the Fourth Quarter and Financial Year ended March 31 2022 (Q4 and FY 2021-22) is available on the Companys website.The recording can be accessed from the link given below:https://supriyalifescience.com/investor-relation/financial/earning-call-recordings/ Kindly take the information on record. |
|
Sat, 21 May 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication With reference to the above captioned subject please find enclosed newspaper advertisement published in Financial Express (English) and Loksatta (Marathi) on Saturday May 21 2022 containing Audited Financial Results for the quarter and year ended March 31 2022. You are requested to kindly take the same on record. |
| Tue, 24 May 2022 |
Opening at High
|
Closing Below Previous Low
|
Close Within 52 Week Low Zone
|
Close Entering 52 Week Low Zone
|
High Decrease 1 Month
|
Equities
M.F.
Sectors